CRANBURY, N.J., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, presented preclinical studies of AT3375 as a monotherapy and in combination with enzyme replacement therapy (ERT) for Gaucher disease during the 8th Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD).
